Vertex Pays $10B for Crinetics' Endocrine Disorder Drug Pipeline

Vertex Pharmaceuticals acquired Crinetics Pharmaceuticals for $10 billion, primarily for its rare endocrine disorder drug portfolio. The deal signals continued consolidation in the biotech space targeting specific hormonal pathways. It means more investment in therapies affecting the body's internal signaling systems.